Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
February 16, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics to Present at Upcoming February Investor Conferences
February 02, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
January 10, 2022 08:00 ET
|
Fate Therapeutics, Inc.
Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress...
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
December 13, 2021 16:31 ET
|
Fate Therapeutics, Inc.
5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve...
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
December 13, 2021 09:01 ET
|
Fate Therapeutics, Inc.
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million...
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
December 08, 2021 17:44 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
November 11, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
November 09, 2021 09:00 ET
|
Fate Therapeutics, Inc.
Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company...
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
November 04, 2021 16:01 ET
|
Fate Therapeutics, Inc.
Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma...
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
November 04, 2021 09:01 ET
|
Fate Therapeutics, Inc.
FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 ...